MariaCatherinePietanzaMD

Oncology • New York, NY

Assistant Professor, Medicine, Weill Cornell Medical College

Join to view full profile

Dr. Pietanza is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pietanza's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10065
Phone+1 212-639-2000

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2004 - 2007
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
State University of New York Downstate Medical Center College of MedicineClass of 2001

Certifications & Licensure

NY State Medical License 2004 - 2025

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2014

Clinical Trials

Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer Start of enrollment: 2008 Aug 01
Completed
Phase 2
Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment Start of enrollment: 2008 Dec 01
Completed
Phase 2
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid Start of enrollment: 2011 May 01
Completed
Phase 1
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Start of enrollment: 2012 Apr 01
Completed
Phase 1
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy Start of enrollment: 2012 Jan 07
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

231 citations
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNO...
Delvys Rodriguez-Abreu, Steven Francis Powell, Maximilian Hochmair, Shirish M. Gadgeel, Emilio Esteban
Annals of Oncology. 2021-07-01
53 citations
Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.
Natasha Rekhtman, Patrice Desmeules, Anna Maria Litvak, M.C. Pietanza, Maria Lauren Santos-Zabala
Modern Pathology. 2019-03-28
3 citations
Reply to F. Liang
M. Catherine Pietanza, Lixia Diao, Jing Wang, Lauren Averett Byers
Journal of Clinical Oncology. 2019-01-08

Lectures

Transitioning From Academic Medicine to a Career in the Pharmaceutical Industry
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member